QED Program Awards $600K to Advance the Commercialization of Three University Technologies

PHILADELPHIA — (January 29, 2018) – Researchers improving the efficiency of bone graft procedures, developing drugs to address treatment-resistant cancer, and advancing research to reverse the invasive potential of cancerous cells will receive a total of $600,000 from the University City Science Center’s QED Proof-of-Concept Program. The program, started in 2009 and now in its tenth round of funding, supports novel university technologies with market potential, bridging the gap between academic research and product commercialization. The awardees were selected from a pool of 54 applicants from 12 academic and research institutions in Pennsylvania, New Jersey and Delaware.

The QED grants will support researchers at New Jersey Institute of Technology, Temple University and The Wistar Institute.  Each team will receive $200,000, half of which will be contributed by the Science Center and half by the researchers’ institutions. Each project will also receive guidance from the Science Center’s experienced team of scientific and business advisors.

Click here to read the full press release.


©2018 PACT All Rights Reserved